1. What Is the Buccal Drug Delivery Market?
The Buccal Drug Delivery Market encompasses pharmaceutical formulations administered via the mucosa of the inner cheek pouch to deliver drugs into the systemic circulation through the buccal epithelium. This route bypasses gastrointestinal degradation and hepatic first-pass metabolism. The market includes buccal tablets, mucoadhesive buccal films, buccal patches, and buccal sprays for hormone replacement, breakthrough cancer pain, nausea management, and acute seizure management. These formulations are administered by patients or caregivers by placing the drug between the cheek and gum and allowing it to dissolve and absorb over minutes. This achieves systemic drug levels faster than oral tablet formulations while avoiding the injection requirement for parenteral delivery. Market scope covers buccal mucoadhesive tablet, film, patch, and spray formulations. It excludes sublingual formulations absorbed beneath the tongue, conventional oral tablets and capsules dissolved after swallowing, and oral mucosal topical treatments without systemic absorption.
2. Buccal Drug Delivery Market Size & Forecast
3. Emerging Technologies
- Mucoadhesive buccal formulation technology is advancing hydrogel polymer systems with optimised mucin binding characteristics that extend drug residence time in the buccal mucosa, improving the fraction of dose absorbed before formulation dissolution. Growing industry adoption of this technology is motivating development.
- Buccal biologic delivery technology is advancing permeation enhancer combinations and nanoparticle-loaded mucoadhesive systems capable of delivering small protein and peptide therapeutics through the buccal epithelium without requiring injection. Growing pharmaceutical interest.
- Controlled-release buccal patch technology is advancing extended adhesion systems that maintain drug release contact with the buccal mucosa for 8 to 24 hours, enabling once-daily or twice-daily systemic dosing. Growing industry adoption of this technology is motivating development.
- The 3D-printed personalised buccal tablet technology is advancing patient-specific drug dosing and release rate customisation through digital formulation design and small-batch additive manufacturing of individual buccal dosage forms. Growing interest in personalised medicine.
Similar technologies are also transforming adjacent markets. Learn more in our Subcutaneous Drug Delivery Market.
4. Key Market Opportunity
A key opportunity in the Buccal Drug Delivery Market is the development of buccal formulations for hormone replacement therapy in the growing population of testosterone-deficient males and peri-menopausal females seeking non-invasive alternatives to injection or gel. A significant proportion of patients requiring testosterone replacement therapy decline or discontinue treatment due to the inconvenience of daily gel application and interpersonal transfer risk, or the discomfort and clinic visit requirements of intramuscular injection regimens. Buccal testosterone delivery offers a patient-managed twice-daily administration with no skin transfer risk and predictable pharmacokinetics, addressing the primary adherence barriers that reduce long-term compliance with transdermal and injection testosterone programmes. Pharmaceutical companies that develop and commercialise improved buccal testosterone and female hormone formulations with demonstrated adherence advantages over existing routes and payer reimbursement for the buccal alternative are positioned to capture a growing share of the expanding hormone replacement therapy market.
5. Top Companies in the Buccal Drug Delivery Market
The following organisations hold leading positions in the Buccal Drug Delivery Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Teva Pharmaceuticals
- Bausch Health
- Endo International
- EUSA Pharma
- Prostrakan (Kyowa Kirin)
- Noven Pharmaceuticals
- Generex Biotechnology
- Corcept Therapeutics
- Eagle Pharmaceuticals
- Shire (Takeda)
6. Market Segmentation
The Buccal Drug Delivery Market is analysed across 5 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Formulation Type | Buccal Tablet Mucoadhesive Buccal Tablet Effervescent Buccal Tablet Buccal Film Mucoadhesive Buccal Film Soluble Buccal Film Buccal Spray Acute Dose Buccal Spray Metered Buccal Spray Buccal Patch Extended-Release Mucoadhesive Patch |
| By Drug Class | Hormone Replacement Buccal Testosterone Buccal Oestrogen Opioid Analgesic Buccal Fentanyl Buccal Buprenorphine Antiemetic Buccal Prochlorperazine Buccal Ondansetron Antiepileptic Buccal Diazepam Buccal Midazolam |
| By Application | Hormone Delivery Testosterone Replacement Female Hormone Therapy Breakthrough Cancer Pain Fentanyl Breakthrough Cancer Nausea and Vomiting Chemotherapy Antiemetic Postoperative Antiemetic Seizure Rescue Acute Seizure Buccal Cluster Seizure Rescue |
| By End User | Hospitals Emergency Department Palliative Care Retail Pharmacy Home Hormone Replacement Outpatient Antiemetic Home Care Self-Administering Buccal Patients Long-Term Care Nursing Home Seizure Rescue |
| By Geography | North America Europe Asia Pacific Latin America Middle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the Buccal Drug Delivery Market trajectory over the forecast period:
Buccal Fentanyl Formulations Are Providing Rapid Breakthrough Cancer Pain Relief for Opioid-Tolerant Cancer Patients with Predictable Pharmacokinetics.Palliative care physicians and oncologists managing opioid-tolerant cancer patients with unpredictable episodic pain breakthrough are specifying buccal fentanyl lozenges. Films as rapid-onset alternatives to oral morphine rescue doses with faster onset appropriate for peak 5-to-15-minute pain intensity. Teva Pharmaceuticals continued commercial development and generic market navigation for its buccal fentanyl Abstral sublingual and Fentora buccal tablet products in 2024, maintaining commercial availability for cancer breakthrough pain prescribers in major global markets.
Buccal Midazolam Has Replaced Rectal Diazepam as the Standard Acute Seizure Rescue Formulation in Paediatric Epilepsy Management.Paediatric neurologists and emergency care teams managing children with refractory epilepsy are adopting buccal midazolam liquid as the preferred out-of-hospital seizure rescue formulation over rectal diazepam due to its easier administration and equivalent. Superior seizure termination speed, bausch Health continued commercial availability of its Buccolam buccal midazolam product and expandedthe formulation across additional European and international markets in 2024. Here buccal midazolam is increasingly replacing rectal diazepam in paediatric epilepsy rescue protocols.
Buccal Testosterone Formulation Technology Is Expanding Hormone Replacement Options Beyond Transdermal Gel and Intramuscular Injection Routes.Endocrinologists and urologists managing male hypogonadism are prescribing buccal testosterone systems as a twice-daily alternative to transdermal gels that avoids transfer to partners and children and provides more consistent testosterone levels than intermittent intramuscular injections. Endo International continued commercial availability and clinical evidence generation for Striant buccal testosterone system in 2024. This targetes the subset of hypogonadal male patients preferring the buccal route over transdermal gel, injection, pellet implant testosterone replacement options.
For related market intelligence, see the Pulmonary Drug Delivery Market.
8. Segmental Analysis
By formulation type, buccal tablets dominated the Buccal Drug Delivery Market in 2025, driven by established commercial use of mucoadhesive buccal tablet formulations for breakthrough cancer pain, hormone replacement, and seizure rescue. Prescribers and pharmacists continue specifying buccal tablets for cancer breakthrough pain and acute seizure rescue as the established clinical evidence base and patient familiarity drive consistent prescription volumes. Buccal films are the fastest-growing formulation type, driven by growing drug developer preference for films offering improved patient handling, reliable dissolution, and more accurate dose measurement than mucoadhesive tablets. Pharmaceutical developers are increasing buccal film programme investment as the thin film dosage form enables precise active surface area specification and patient-preferred administration aesthetics over conventional tablet counterparts.
By application, hormone delivery dominated the Buccal Drug Delivery Market in 2025, driven by established buccal testosterone replacement prescription volumes and patient preference for buccal administration over gel or injection. Endocrinologists and urologists continue prescribing buccal testosterone as a twice-daily alternative for patients who cannot use transdermal gel due to transfer concerns or cannot tolerate intramuscular injection discomfort. Breakthrough cancer pain management is the fastest-growing application, driven by growing cancer incidence, expanding palliative care capacity, and increasing oncologist adoption of rapid-onset buccal fentanyl as standard breakthrough pain rescue. Palliative care physicians are increasing buccal fentanyl prescribing as evidence demonstrates superior onset speed over oral morphine rescue and growing reimbursement access expands prescription volumes at oncology centres.
9. Regional Analysis
Regional demand patterns across the Buccal Drug Delivery Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America accounted for the largest share of the Buccal Drug Delivery Market in 2025, holding 40.0% of the global market. The region's dominance reflects the large palliative care and breakthrough cancer pain patient population prescribing buccal fentanyl, established prescription coverage for buccal hormone replacement formulations, and the concentration of buccal drug delivery pharmaceutical companies in the United States. Medicare and private payer coverage for approved buccal drug products across cancer breakthrough pain and hormone replacement indications generates consistent per-patient prescription volumes at specialty and retail pharmacies across North America. Advanced palliative care programme infrastructure at United States cancer centres generates consistent demand for buccal fentanyl and antiemetic formulations as components of cancer pain and chemotherapy adjunct management.
Highest CAGR Region
Asia Pacific is expected to register the highest CAGR of 9.80% during the forecast period. Growing cancer incidence, expanding palliative care programme development, and increasing awareness of rapid-onset breakthrough pain management formulations in China, Japan, South Korea, and Australia are creating demand for buccal fentanyl and opioid analgesic products. Growing paediatric neurology programme capacity and increasing buccal midazolam awareness among epilepsy specialists in Japan, South Korea, and Australia are creating demand for buccal seizure rescue formulations as alternatives to rectal diazepam in acute management. Expanding male hormone deficiency treatment awareness and growing testosterone replacement prescribing in Japan and South Korea are creating demand for buccal testosterone formulations as alternatives to injection and transdermal patch routes.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology Adoption Trends and Innovation Tracking
- • Custom Company Profiling and Benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country-Level Opportunity Mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The Buccal Drug Delivery Market was valued at USD 1.87 Bn in 2025 and is projected to reach USD 3.24 Bn by 2034, growing at a CAGR of 6.30% over the 2026–2034 forecast period.
The Buccal Drug Delivery Market is projected to grow at a CAGR of 6.30% from 2026 to 2034.
North America accounted for the largest share of the Buccal Drug Delivery Market in 2025, holding 40.0% of the global market.
The leading companies in the Buccal Drug Delivery Market include Teva Pharmaceuticals, Bausch Health, Endo International, EUSA Pharma, Prostrakan (Kyowa Kirin), Noven Pharmaceuticals, Generex Biotechnology, Corcept Therapeutics, Eagle Pharmaceuticals, Shire (Takeda).
Buccal fentanyl formulations are providing rapid breakthrough cancer pain relief for opioid-tolerant cancer patients with predictable pharmacokinetics.
By formulation type, buccal tablets dominated the Buccal Drug Delivery Market in 2025, driven by established commercial use of mucoadhesive buccal tablet formulations for breakthrough cancer pain, hormone replacement, and seizure rescue.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.